Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA-Mutated Ovarian Carcinoma”

71 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 71 results

Testing effectiveness (Phase 2)WithdrawnNCT01661868
What this trial is testing

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Dana-Farber Cancer Institute
Not applicableLooking for participantsNCT03667417
What this trial is testing

Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation

Who this might be right for
Breast CancersOvarian Cancers
Institut Paoli-Calmettes 5,000
Not applicableLooking for participantsNCT06588322
What this trial is testing

Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy

Who this might be right for
Ovarian Cancer
Institut Claudius Regaud 130
Testing effectiveness (Phase 2)Study completedNCT02983799
What this trial is testing

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 272
Large-scale testing (Phase 3)Study completedNCT03402841
What this trial is testing

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

Who this might be right for
Non-Germline BRCA Mutated Ovarian Cancer
AstraZeneca 279
Not applicableActive Not RecruitingNCT05748353
What this trial is testing

Endocrine Disruptors and Life STILe in Breast Cancer Development

Who this might be right for
Breast CancerBRCA1 MutationBRCA2 Mutation+3 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 275
Early research (Phase 1)Study completedNCT01445418
What this trial is testing

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Who this might be right for
Breast CancerOvarian Cancer
National Cancer Institute (NCI) 103
Not applicableNo Longer AvailableNCT03063710
What this trial is testing

Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

Who this might be right for
PSR Ovarian Cancer With a BRCA Mutation
AstraZeneca
Not applicableActive Not RecruitingNCT06497270
What this trial is testing

A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY Trial

Who this might be right for
BRCA MutationEstrogen DeficiencySurgical Menopause+3 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 3
Early research (Phase 1)Study completedNCT01104259
What this trial is testing

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerHereditary Breast/Ovarian Cancer - BRCA1+6 more
University of Washington 50
Not applicableEnded earlyNCT03203993
What this trial is testing

China Ovarian Cancer BRCA Testing Study

Who this might be right for
Ovarian Cancer
AstraZeneca 29
Not applicableStudy completedNCT03471572
What this trial is testing

Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India

Who this might be right for
Ovarian Cancer
AstraZeneca 240
Large-scale testing (Phase 3)WithdrawnNCT02392676
What this trial is testing

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Who this might be right for
Platinum Sensitive Relapsed Ovarian Cancer
AstraZeneca
Not applicableLooking for participantsNCT05769517
What this trial is testing

PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEALTHY OVARIES

Who this might be right for
BRCA MutationOvarian CancerUltrasound Therapy; Complications
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1,300
Not applicableActive Not RecruitingNCT01907789
What this trial is testing

Prophylactic Salpingectomy With Delayed Oophorectomy

Who this might be right for
Ovarian Carcinoma
M.D. Anderson Cancer Center 80
Early research (Phase 1)Study completedNCT05258747
What this trial is testing

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Who this might be right for
Ovarian CancerBreast Cancer
Sandoz 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT02571725
What this trial is testing

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
New Mexico Cancer Research Alliance 50
Testing effectiveness (Phase 2)Study completedNCT01367639
What this trial is testing

Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers

Who this might be right for
Hereditary Breast and Ovarian Cancer Syndrome
Sheba Medical Center 67
Large-scale testing (Phase 3)Active Not RecruitingNCT01844986
What this trial is testing

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Who this might be right for
Newly DiagnosedAdvanced Ovarian CancerFIGO Stage III-IV+4 more
AstraZeneca 450
Early research (Phase 1)Not Yet RecruitingNCT07088588
What this trial is testing

Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid CancerMetastatic Solid TumorOvarian Cancer+3 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd 105
Load More Results